32 results
CORRESP
RGBP
Regen BioPharma Inc
22 Nov 13
Correspondence with SEC
12:00am
with the United States Food and Drug Administration to initiate a clinical trial In this study we will seek to determine the safety and potential … of safety in an immune deficient model by intravenous administration bracketing the per kilogram dose proposed in the clinical study;
b) augmentation
424B3
RGBP
Regen BioPharma Inc
19 Mar 14
Prospectus supplement
12:00am
will seek to determine the safety and potential efficacy of intravenously administered autologous (derived or transferred from the same individual's … to the IND filed by the Company for HemaXellerate I
a) demonstration of safety in an immune deficient model by intravenous administration bracketing
10-K
2014 FY
RGBP
Regen BioPharma Inc
18 Dec 14
Annual report
12:00am
and Drug Administration to initiate a clinical trial. In this study we will seek to determine the safety and potential efficacy of intravenously … to initiate a Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating
424B3
jrsmy
20 Nov 23
Prospectus supplement
9:38am
424B3
z09598fv1m kn3
15 May 23
Prospectus supplement
10:25am
424B3
m9lpq4
2 Oct 23
Prospectus supplement
1:42pm